![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, June 03, 2012 11:17:54 AM
The trial, involving 1,088 patients who had stopped responding to traditional hormonal drugs but had not been treated with chemotherapy, found that Zytiga slowed the spread of the disease by 58 percent.
Zytiga is one of several new prostate cancer treatments that may significantly prolong the life of patients by zeroing in more closely on certain mechanisms that help tumors proliferate. New data on the medications are being presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
The drug's robust results in earlier-stage cancer - it is already approved for men with prostate cancer who previously received chemotherapy - have implications for companies like Dendreon, which sells therapeutic prostate cancer vaccine Provenge, and Medivation, which is developing a drug with a mechanism of action similar to Zytiga's.
The Zytiga trial found that patients given a placebo and the steroid prednisone went a median of 8.3 months before their disease worsened. Patients treated with the steroid and Zytiga were still faring better at the time the data were analyzed, so a comparable statistic was not yet available.
The study's lead investigator, Dr Charles Ryan of the University of California, San Francisco's Helen Diller Family Comprehensive Cancer Center, estimated that the Zytiga patients would enjoy at least 16 months of progression free survival (PFS).
The trial also found that prednisone-only patients lived for a median of 27.2 months. Overall survival for patients treated with Zytiga had also not yet been reached, but J&J estimated that it improved their survival by 33 percent, or 9 months.
That would clearly surpass the 4.1 month survival benefit demonstrated by Provenge, which was tested in a similar patient population.
"We believe the perception is that this is clearly negative for Provenge," JP Morgan analyst Cory Kasimov said in a research note, while emphasizing that he believes physicians will still see a place for using immunotherapies such as the Dendreon drug.
The Zytiga pre-chemotherapy trial was stopped ahead of schedule in March after it became clear patients were benefiting from the drug, a member of a new class designed to work inside cancer cells to block the production of testosterone, the male hormone that fuels prostate cancer cell growth.
Prostate cancer is the second most common form of cancer in men, with some 30,000 dying from the disease each year in the United States alone and 250,000 globally. Around a third of patients need no treatment, because their disease does not metastasize, or spread, while another third are treated and cured.
But for the remaining patients, the cancer will recur following treatment or spread to the bones, lymph nodes or other parts of the body. Prostate cancer can turn lethal when it spreads and when it resists standard hormonal therapy.
NEW APPROVAL SOUGHT
Research presented at ASCO showed that a pivotal trial of Medivation's enzalutamide met all of its secondary goals - including improvements in quality of life.
Medivation and development partner Astellas Pharma, which previously said the experimental drug improved survival by nearly 5 months in a trial of advanced prostate cancer patients, filed in May for U.S. regulatory approval of enzalutamide.
Details released on Saturday included data showing that the Medivation drug, designed to block testosterone from binding to cancer cells, reduced the risk of skeletal-related events, including fractures, by 38 percent.
Data will also be presented at ASCO from trials of alpharadin, a drug designed to deliver minute, highly-charged doses of radiation to secondary tumors in the bone that is being developed by Bayer AG and Algeta ASA.
J&J expects to file in the second half of this year for U.S. regulatory approval of Zytiga, also known as abiraterone, as a treatment for men with metastatic prostate cancer who have not yet received chemotherapy.
"Clearly, if we're showing greater benefit in the pre-chemotherapy population ... I don't think its unreasonable that they (clinicians) would move it up," said Michael Meyers, head of the drug's development at J&J.
The study also showed that Zytiga significantly delayed the need for pain drugs taken to reduce side effects and eventual chemotherapy.
The drug is currently given for eight months at a cost of around $44,000. Barclays estimates peak U.S. Zytiga sales of $1.5 billion by 2015, with $700 million from cases where it is used after chemotherapy and $800 million from patients who have yet to try chemo.
Side effects associated with the drug included cardiac disorders, high blood pressure and increased liver enzyme levels.
J&J's Meyers said the safety profile seen with Zytiga in the latest trial was similar to earlier studies, even though patients were exposed to the drug for nearly twice as long.
He said the side effects "for the most part did not disrupt treatment and were easily managed by routine medical interventions."
Recent JNJ News
- Johnson & Johnson Completes Acquisition of Proteologix, Inc. • Business Wire • 06/21/2024 11:30:00 AM
- Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease • PR Newswire (US) • 06/20/2024 08:30:00 PM
- More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme • Business Wire • 06/20/2024 05:07:00 PM
- TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction • PR Newswire (US) • 06/20/2024 12:00:00 PM
- Trump Media Resells Stocks and Warrants; KB Home Exceeds Q2 Expectations, and More News • IH Market News • 06/20/2024 10:55:11 AM
- Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products • Business Wire • 06/17/2024 09:55:00 PM
- Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer • PR Newswire (US) • 06/17/2024 12:00:00 PM
- Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study • PR Newswire (US) • 06/15/2024 07:30:00 AM
- TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma • PR Newswire (US) • 06/14/2024 12:00:00 PM
- Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy • Business Wire • 06/12/2024 06:26:00 PM
- Paramount Ends Skydance Talks, Oracle Shares Surge 8.7% on New Partnerships, and More News • IH Market News • 06/12/2024 11:19:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 09:07:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 09:07:29 PM
- Apollo Buys 49% of Intel’s Irish Plant for $11bn, BlackRock and Citadel to Create Texas Exchange, and More News • IH Market News • 06/05/2024 11:41:36 AM
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results • Business Wire • 06/04/2024 08:30:00 PM
- Johnson & Johnson Completes Acquisition of Shockwave Medical • Business Wire • 05/31/2024 12:45:00 PM
- Sarepta Therapeutics Set to Join S&P MidCap 400 • PR Newswire (US) • 05/29/2024 09:48:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/28/2024 08:10:27 PM
- Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis • GlobeNewswire Inc. • 05/28/2024 11:35:00 AM
- Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis • Business Wire • 05/28/2024 11:30:00 AM
- Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation • Business Wire • 05/22/2024 04:05:00 PM
- Form CERT - Certification by an exchange approving securities for listing • Edgar (US Regulatory) • 05/21/2024 02:43:01 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 05/20/2024 09:17:51 PM
- Form 8-A12B - Registration of securities [Section 12(b)] • Edgar (US Regulatory) • 05/20/2024 08:34:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:01:37 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM